Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) Non Operating Income (2019 - 2025)

Historic Non Operating Income for Revolution Medicines (RVMD) over the last 7 years, with Q3 2025 value amounting to $10.1 million.

  • Revolution Medicines' Non Operating Income fell 4819.3% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.3 million, marking a year-over-year decrease of 1290.14%. This contributed to the annual value of $88.7 million for FY2024, which is 8750.37% up from last year.
  • Latest data reveals that Revolution Medicines reported Non Operating Income of $10.1 million as of Q3 2025, which was down 4819.3% from $16.9 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Non Operating Income ranged from a high of $27.3 million in Q1 2025 and a low of $221000.0 during Q1 2021
  • In the last 5 years, Revolution Medicines' Non Operating Income had a median value of $10.1 million in 2025 and averaged $10.5 million.
  • In the last 5 years, Revolution Medicines' Non Operating Income crashed by 7511.26% in 2021 and then soared by 223741.72% in 2023.
  • Revolution Medicines' Non Operating Income (Quarter) stood at $237000.0 in 2021, then skyrocketed by 2042.19% to $5.1 million in 2022, then soared by 270.08% to $18.8 million in 2023, then grew by 11.7% to $21.0 million in 2024, then crashed by 52.05% to $10.1 million in 2025.
  • Its Non Operating Income stands at $10.1 million for Q3 2025, versus $16.9 million for Q2 2025 and $27.3 million for Q1 2025.